After raising more than $142 million in venture capital earlier this year to support its liver transplant technology, OrganOx ...

Another cell therapy biotech has run out of steam, this time before ever reaching the clinic. | Another cell therapy biotech ...

The candidates are sourced from Arnatar’s next-gen RNA discovery engine, dubbed DARGER for dual-functional antisense RNA for ...

Gumokimab, also called AK111, is an anti-IL-17A monoclonal antibody that Akeso has already tested out in a separate phase 3 ...

Amid a frozen-over IPO landscape, LB Pharmaceuticals has filed to go public to fund a pivotal schizophrenia study for its ...

At AbbVie, bretisilocin will slot into a well-established neuroscience unit. AbbVie has deals with Gedeon Richter, the source ...

With the FDA’s go-ahead, Coya plans to launch a multicenter phase 2 trial of COYA 302 in patients with ALS, CEO Arun ...

PDS Biotech has reported final phase 2 data on PDS0101 in the tough-to-treat head and neck cancer setting, linking a combination of the immunotherapy and Keytruda to median overall survival (OS) of 39 ...

By: Raymund Santos, Senior Manager, Quality Control Bioanalytics, AGC BiologicsAelén Mabillé, Manager, Quality Control Raw ...

The Supreme Court is allowing the Trump administration to ax $783 million in federal research funding, reversing a lower ...

Lighthouse Pharmaceuticals’ plan to become a beacon of hope for Alzheimer’s disease patients has received almost $50 million ...

Jazz Pharmaceuticals has struck a deal to bolster its epilepsy ambitions, paying Saniona $42.5 million upfront for a ...